Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion. Rznomics will ...

Eli Lilly & Co. said Tuesday it’s cutting ... as there were shortages and a high patient need. Against that background, Lilly ...

Eli Lilly has a lot going for it ... Lilly was also working on something else in the background. As Novo Nordisk did, Lilly developed an alternative version of its diabetes drug -- Zepbound ...

th { background-color: #293a5a ... Upon a comprehensive analysis of Eli Lilly, the following trends can be discerned: The Price to Earnings ratio of 112.95 for this company is 4.17x above the ...

This background helps highlight how important Eli Lilly's most recent brand-new approval is. The company earned the thumbs-up from the U.S. Food and Drug Administration (FDA) for Kisunla ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Eli Lilly is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so.Trading at $852 per share, LLY ...

Eli Lilly LLY-0.21%decrease; red down pointing triangle revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged ...